OBI Pharma Presents Preclinical Results for Bispecific ADC OBI-201 at SABCS 2025 - OBI Pharma 台灣浩鼎 Highlighting OBI-201’s Antitumor Activity and Payload Delivery Performance Across Multiple Tumor Animal Models OBI Pharma (4174.TWO) presented the preclinical results of OBI-201, at the 2025 San Anton...

🎉OBI presented new preclinical results for our bispecific ADC OBI-201 at
@sabcs.bsky.social #SABCS2025, led by our CSO Ya-Chi Chen and the R&D team.
#OBIPharma #OBI201 #ADC #BispecificADC #SABCS2025 #BreastCancerResearch #TROP2

www.obipharma.com/news/obi-201...